Navigation Links
Novel technology detects human DNA mutations

Researchers at Nanosphere, Inc. today reported unprecedented benefits in the company's technology for the medical analysis of human DNA.

Nanosphere's nanoparticle-based technology allows for rapid, highly-sensitive and specific Single Nucleotide Polymorphism (SNP) genotyping, which is the direct detection of a particular gene and the extent to which it is normal or mutated. The technology, reported in the February 2005 (Volume 33, Number 2), issue of Nucleic Acids Research, allows detection of a SNP in an unknown genotype with a greater than 99 percent confidence threshold and can be used with human DNA obtained from samples as small as a drop of blood. Importantly, the technology eliminates the need for costly, time and labor intensive gene amplification or enzymatic interventions ?two widespread methods currently used to perform such analyses.

"Nanosphere's new SNP analysis methodology for whole genomic human DNA is a powerful example of the versatility of our proprietary ClearReadTM nanoparticle technology," said William Moffitt, Nanosphere's President and CEO. "This study and the use of nanoparticles to dramatically increase sensitivity in our other proprietary applications -- such as bio-barcode for ultra sensitive detection of proteins -- demonstrate the broad applicability of nanotechnology and its potential to markedly advance the state-of-the-art in nucleic acid and proteomic research and diagnostics." The analysis of whole human genomic DNA is extraordinarily complex as it requires sifting through the more than one billion base pairs of DNA to find a particular base pair of interest. Once that base pair is located, it is then necessary to determine if either of the bases is mutated (i.e., has SNPs). Nanosphere's technology can rapidly, easily, and accurately interrogate both bases in the pair to determine if they are homozy gous (i.e., both are mutant or normal) or heterozygous (i.e., one is mutant, one is normal) ?the most critical step in correlating the SNP with a disease or drug sensitivity. To do so, Nanosphere scientists employ a two-step process called ClearReadTM technology. This method sandwiches a target DNA SNP segment between two oligonucleotide sequences to greatly increase detection specificity and sensitivity. One segment identifies any mutations in the DNA and the probe, a highly sensitive gold nanoparticle, creates a strong signal accurately indicating the presence of a specific target SNP. Proof of principle, reproducibility, and the robust, simple and rapid characteristics of this technology were demonstrated with unamplified DNA samples representing all possible forms of three genes implicated in hypercoagulation disorders. Related : Nanosphere Inc. Technology
'"/>

Source:Eurekalert


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel antiviral technology inhibits RSV infection in mice
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
5. Discovery Could Lead To Novel Approaches In HIV Treatment
6. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
7. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
8. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
9. Novel live reporting system to track cells
10. Field of beams - Novel system uses polarized light pulses to reveal crop health
11. Novel compounds show promise as safer, more potent insecticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... -- UCHealth ( Aurora, Colorado ) becomes ... patient management. In addition to optimizing care coordination for ... lung, UCHealth looks to improve provider workflow by decreasing ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, ... Excel spreadsheet, which was extremely arduous and susceptible to ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... , Feb. 16, 2017 Paradigm Diagnostics ... B financing, adding an additional $3M from New Sciences ... Verde Venture Partners and other strategic partners at the ... further accelerating commercial adoption of their flagship Paradigm Cancer ... expanding the Paradigm cancer registry. Dr. ...
Breaking Biology Technology: